ESMO expert Rodrigo Dienstmann comments on the findings of the RANGE and CheckMate 214 trials, presented at the second Presidential symposium at the ESMO 2017 Congress in Madrid, Spain.
04-10-2017 | Genitourinary cancers | ESMO 2017 | Video
Browse specialties
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs
ctDNA and bladder cancer: Current understanding and beyond
ROS1 fusion-positive NSCLC
NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC
Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy
ALK fusion-positive NSCLC: International approaches to management
RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC
COVID-19 & cancer
Conferences